Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORESM Registry
| Autor: | U. Trostmann, Víctor José González Ramallo, Artur Timerman, Kamel Bouylout, JB Sarma, Armando Gonzalez-Ruiz, Kamal Hamed, Rashidkhan Pathan, Panayiotis Gargalianos-Kakolyris |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Male medicine.medical_specialty Registry Staphylococcus aureus Asia Adolescent Bacteremia Staphylococcal infections medicine.disease_cause Young Adult Daptomycin mental disorders polycyclic compounds medicine Humans In patient Pharmacology (medical) Intensive care medicine Gram-positive bacterial infections Gram-Positive Bacterial Infections Original Research Aged Retrospective Studies Medicine(all) business.industry Soft Tissue Infections Retrospective cohort study General Medicine Skin Diseases Bacterial Middle Aged Staphylococcal Infections bacterial infections and mycoses medicine.disease Anti-Bacterial Agents Europe Latin America Clinical response lipids (amino acids peptides and proteins) Observational study Female Safety business Gram-positive infections medicine.drug |
| Zdroj: | Advances in Therapy |
| ISSN: | 0741-238X |
| DOI: | 10.1007/s12325-015-0220-6 |
| Popis: | Introduction The aim of this study was to evaluate the clinical outcomes and safety of daptomycin therapy in patients with serious Gram-positive infections. Methods Patients were enrolled in the European Cubicin® Outcomes Registry and Experience (EU-CORESM), a non-interventional, multicenter, observational registry. The real-world data were collected across 18 countries (Europe, Latin America, and Asia) for patients who had received at least one dose of daptomycin between January 2006 and April 2012. Two-year follow-up data were collected until 2014 for patients with endocarditis, intracardiac/intravascular device infection, osteomyelitis, or orthopedic device infection. Results A total of 6075 patients were enrolled. The most common primary infections were complicated skin and soft tissue infection (31.7%) and bacteremia (20.7%). Staphylococcus aureus was the most frequently reported pathogen (42.9%; methicillin-resistant S. aureus [MRSA], 23.2%), followed by Staphylococcus epidermidis and other coagulase-negative staphylococci (CoNS, 28.5%). The most commonly prescribed dose of daptomycin was 6 mg/kg/day (43.6%), and the median duration of therapy was 11 (range 1–300) days. Overall clinical success rate was 80.5%, and was similar whether daptomycin was used as first-line (82.9%) or second-line (79.2%) therapy. Clinical success rates were high in patients with S.aureus (83.9%; MRSA 83.0%) and CoNS (including S. epidermidis, 82.5%) infections. The majority of patients with endocarditis or intracardiac/intravascular device infection (86.7%) or osteomyelitis/orthopedic device infection (85.9%) had a sustained response during the 2-year follow-up period. There were no new or unexpected safety findings. Conclusion Results from real-world clinical experience showed that daptomycin is a valuable therapeutic option in the management of various difficult-to-treat Gram-positive infections. Funding This study was funded by Novartis Pharma AG. Electronic supplementary material The online version of this article (doi:10.1007/s12325-015-0220-6) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|